JP2016524611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016524611A5 JP2016524611A5 JP2016515080A JP2016515080A JP2016524611A5 JP 2016524611 A5 JP2016524611 A5 JP 2016524611A5 JP 2016515080 A JP2016515080 A JP 2016515080A JP 2016515080 A JP2016515080 A JP 2016515080A JP 2016524611 A5 JP2016524611 A5 JP 2016524611A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- cancer
- vegf
- fgf2
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 66
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 49
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 49
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 47
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 47
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 45
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 45
- 230000004927 fusion Effects 0.000 claims 32
- 238000000034 method Methods 0.000 claims 30
- 108020004999 messenger RNA Proteins 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 16
- 206010027406 Mesothelioma Diseases 0.000 claims 9
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 9
- 201000007270 liver cancer Diseases 0.000 claims 8
- 208000014018 liver neoplasm Diseases 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 6
- 238000003364 immunohistochemistry Methods 0.000 claims 6
- 229960000639 pazopanib Drugs 0.000 claims 6
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical group C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 238000003757 reverse transcription PCR Methods 0.000 claims 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 108010081667 aflibercept Proteins 0.000 claims 4
- 229960002833 aflibercept Drugs 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 229960003005 axitinib Drugs 0.000 claims 4
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 4
- 229960000397 bevacizumab Drugs 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 238000009097 single-agent therapy Methods 0.000 claims 4
- 229960003787 sorafenib Drugs 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 229960001796 sunitinib Drugs 0.000 claims 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 229960004562 carboplatin Drugs 0.000 claims 3
- 190000008236 carboplatin Chemical compound 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 3
- 229960005079 pemetrexed Drugs 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- -1 bevacizumab Chemical compound 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000004797 therapeutic response Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000013074 reference sample Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826975P | 2013-05-23 | 2013-05-23 | |
| US61/826,975 | 2013-05-23 | ||
| US201461936471P | 2014-02-06 | 2014-02-06 | |
| US61/936,471 | 2014-02-06 | ||
| US201461974279P | 2014-04-02 | 2014-04-02 | |
| US61/974,279 | 2014-04-02 | ||
| PCT/US2014/039129 WO2014190147A2 (en) | 2013-05-23 | 2014-05-22 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018169261A Division JP2019023193A (ja) | 2013-05-23 | 2018-09-11 | がんを治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016524611A JP2016524611A (ja) | 2016-08-18 |
| JP2016524611A5 true JP2016524611A5 (enExample) | 2017-07-13 |
Family
ID=51934346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515080A Pending JP2016524611A (ja) | 2013-05-23 | 2014-05-22 | がんを治療する方法 |
| JP2018169261A Pending JP2019023193A (ja) | 2013-05-23 | 2018-09-11 | がんを治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018169261A Pending JP2019023193A (ja) | 2013-05-23 | 2018-09-11 | がんを治療する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9775881B2 (enExample) |
| EP (2) | EP2999799A4 (enExample) |
| JP (2) | JP2016524611A (enExample) |
| KR (1) | KR20160013092A (enExample) |
| CN (1) | CN105307669A (enExample) |
| AU (1) | AU2014268519A1 (enExample) |
| BR (1) | BR112015029145A2 (enExample) |
| CA (1) | CA2909689A1 (enExample) |
| HK (1) | HK1219513A1 (enExample) |
| MX (1) | MX2015015426A (enExample) |
| RU (1) | RU2015154985A (enExample) |
| SG (2) | SG11201509596YA (enExample) |
| WO (1) | WO2014190147A2 (enExample) |
| ZA (1) | ZA201507762B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014190147A2 (en) * | 2013-05-23 | 2014-11-27 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| CN106413739B (zh) * | 2014-12-09 | 2019-09-17 | 张文涛 | Nbp158及其用途 |
| GB201609402D0 (en) * | 2016-05-27 | 2016-07-13 | Cancer Res Inst Royal | Materials and methods for treating cancer |
| JP2021518532A (ja) * | 2018-03-16 | 2021-08-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | がんにおける治療薬に対する応答の分析 |
| KR20240003755A (ko) * | 2022-06-29 | 2024-01-09 | 고려대학교 산학협력단 | 인간 FcγRs 결합력이 제거된 당화 Fc 변이체들 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| EP2338915A3 (en) | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| EP1125584A4 (en) | 1998-10-30 | 2005-01-12 | Takeda Chemical Industries Ltd | PREPARATIONS CONTAINING BETACELLULIN PROTEIN |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| IL151865A0 (en) | 2000-03-31 | 2003-04-10 | Genentech Inc | Compositions and methods for detecting and quantifying gene expression |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| CA2597682A1 (en) * | 2005-02-14 | 2006-08-24 | Florida State University Research Foundation, Inc. | C10 cyclopropyl ester substituted taxane compositions |
| EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US20090105329A1 (en) * | 2005-11-04 | 2009-04-23 | Judy Chiao | Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies |
| CL2007003411A1 (es) * | 2006-11-28 | 2008-07-04 | Centelion | Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu |
| EP2637020A3 (en) | 2007-06-29 | 2014-01-08 | Correlogic Systems Inc. | Predictive markers for ovarian cancer |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| NZ703786A (en) * | 2010-11-15 | 2016-08-26 | Five Prime Therapeutics Inc | Fgfr1 extracellular domain combination therapies |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| RU2013154355A (ru) * | 2011-06-03 | 2015-07-20 | Ф. Хоффманн-Ля Рош Аг | Способ лечения мезотелиомы ингибитором рi3к |
| WO2014190147A2 (en) * | 2013-05-23 | 2014-11-27 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
-
2014
- 2014-05-22 WO PCT/US2014/039129 patent/WO2014190147A2/en not_active Ceased
- 2014-05-22 CN CN201480028853.4A patent/CN105307669A/zh active Pending
- 2014-05-22 KR KR1020157035893A patent/KR20160013092A/ko not_active Withdrawn
- 2014-05-22 US US14/890,047 patent/US9775881B2/en active Active
- 2014-05-22 AU AU2014268519A patent/AU2014268519A1/en not_active Abandoned
- 2014-05-22 JP JP2016515080A patent/JP2016524611A/ja active Pending
- 2014-05-22 BR BR112015029145A patent/BR112015029145A2/pt not_active IP Right Cessation
- 2014-05-22 SG SG11201509596YA patent/SG11201509596YA/en unknown
- 2014-05-22 HK HK16107529.7A patent/HK1219513A1/zh unknown
- 2014-05-22 EP EP14800459.1A patent/EP2999799A4/en not_active Withdrawn
- 2014-05-22 CA CA2909689A patent/CA2909689A1/en not_active Abandoned
- 2014-05-22 RU RU2015154985A patent/RU2015154985A/ru not_active Application Discontinuation
- 2014-05-22 SG SG10201703977UA patent/SG10201703977UA/en unknown
- 2014-05-22 EP EP17177845.9A patent/EP3252171B8/en active Active
- 2014-05-22 MX MX2015015426A patent/MX2015015426A/es unknown
-
2015
- 2015-10-16 ZA ZA2015/07762A patent/ZA201507762B/en unknown
-
2018
- 2018-09-11 JP JP2018169261A patent/JP2019023193A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kienast et al. | Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy | |
| Clarke et al. | Understanding and targeting resistance to anti-angiogenic therapies | |
| Lazăr et al. | New advances in targeted gastric cancer treatment | |
| Deng et al. | Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges | |
| Clarke et al. | Targeted inhibition of VEGF receptor 2: an update on ramucirumab | |
| Chan et al. | Targeted therapy for non-small cell lung cancer: current standards and the promise of the future | |
| Rougier et al. | Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer | |
| Cheng et al. | Molecularly targeted drugs for metastatic colorectal cancer | |
| Aprile et al. | Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use | |
| Wang et al. | Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma | |
| Li et al. | Current molecular targeted therapy in advanced gastric cancer: A comprehensive review of therapeutic mechanism, clinical trials, and practical application | |
| Rivera et al. | Cetuximab, its clinical use and future perspectives | |
| Eroglu et al. | Targeting angiopoietin-2 signaling in cancer therapy | |
| Jitawatanarat et al. | Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib | |
| JP2016524611A5 (enExample) | ||
| Vergote et al. | A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma | |
| Balsano et al. | State of the art for metastatic pancreatic cancer treatment: Where are we now? | |
| Lee et al. | Options for second-line treatment in metastatic colorectal cancer | |
| Lee et al. | Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors | |
| He et al. | The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC) | |
| Mok et al. | Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial | |
| Koukourakis et al. | Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer | |
| Wang et al. | Advances in drugs targeting lymphangiogenesis for preventing tumor progression and metastasis | |
| Schweizer et al. | From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer | |
| Jackson et al. | Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence |